Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP881698.RASfBB-ywYem4RwU4RCqt5cD_9a9S3_xGo69DI6NUnTv4130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP881698.RASfBB-ywYem4RwU4RCqt5cD_9a9S3_xGo69DI6NUnTv4130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP881698.RASfBB-ywYem4RwU4RCqt5cD_9a9S3_xGo69DI6NUnTv4130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP881698.RASfBB-ywYem4RwU4RCqt5cD_9a9S3_xGo69DI6NUnTv4130_provenance.
- NP881698.RASfBB-ywYem4RwU4RCqt5cD_9a9S3_xGo69DI6NUnTv4130_assertion description "[Understanding the role of the PI3K/AKT pathway in FSH-stimulated expression of survivin and VEGF will be beneficial for evaluating the prognosis for patients with ovarian serous cystadenocarcinoma and for pursuing effective treatment against this disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881698.RASfBB-ywYem4RwU4RCqt5cD_9a9S3_xGo69DI6NUnTv4130_provenance.
- NP881698.RASfBB-ywYem4RwU4RCqt5cD_9a9S3_xGo69DI6NUnTv4130_assertion evidence source_evidence_literature NP881698.RASfBB-ywYem4RwU4RCqt5cD_9a9S3_xGo69DI6NUnTv4130_provenance.
- NP881698.RASfBB-ywYem4RwU4RCqt5cD_9a9S3_xGo69DI6NUnTv4130_assertion SIO_000772 18574502 NP881698.RASfBB-ywYem4RwU4RCqt5cD_9a9S3_xGo69DI6NUnTv4130_provenance.
- NP881698.RASfBB-ywYem4RwU4RCqt5cD_9a9S3_xGo69DI6NUnTv4130_assertion wasDerivedFrom befree-20140225 NP881698.RASfBB-ywYem4RwU4RCqt5cD_9a9S3_xGo69DI6NUnTv4130_provenance.
- NP881698.RASfBB-ywYem4RwU4RCqt5cD_9a9S3_xGo69DI6NUnTv4130_assertion wasGeneratedBy ECO_0000203 NP881698.RASfBB-ywYem4RwU4RCqt5cD_9a9S3_xGo69DI6NUnTv4130_provenance.
- befree-20140225 importedOn "2014-02-25" NP881698.RASfBB-ywYem4RwU4RCqt5cD_9a9S3_xGo69DI6NUnTv4130_provenance.